Indirect assays have claimed to quantify phytate (InsP₆) levels in human biofluids, but these have been based on the initial assumption that InsP₆ is there, an assumption that our more direct assays disprove. We have shown that InsP₆ does not and cannot (because of the presence of an active InsP₆ phosphatase in serum) exist in mammalian serum or urine. Therefore, any physiological effects of dietary InsP₆ can only be due either to its actions in the gut as a polyvalent cation chelator, or to inositol generated by its dephosphorylation by gut microflora.

We are grateful to Dr Vucenik for bringing up a number of interesting points.

It is true that we have not quantified the dietary intakes of our human donors any more (but also hardly any less) than has been done by those groups claiming that InsP₆ is present in bodily fluids. As a qualitative observation we should point out that in fact all our donors for ref. [1] do have a regular intake of dietary cereals and indeed, one is a strict vegetarian on a high cereal diet. But it is quantification that reveals this to be a specious issue. The limits of detection in our two relevant publications [1,2] for InsP₆ in plasma and urine were, respectively, around two and three orders of magnitude lower than the levels claimed to be present by Grases et al. [3] in the fluids of experimentally phytate-deprived human subjects. These numbers make the argument that we could not detect any InsP₆ simply because we chose donors on the ‘wrong’ diet untenable.

So how have those many claims that InsP₆ is present in body fluids come about? For most of them, the simple answer appears to be that the assays used are indirect and are based entirely on the assumption that InsP₆ is present in bodily fluids. As a qualitative observation we should point out that in fact all our donors for ref. [1] do have a regular intake of dietary cereals and indeed, one is a strict vegetarian on a high cereal diet. But it is quantification that reveals this to be a specious issue. The limits of detection in our two relevant publications [1,2] for InsP₆ in plasma and urine were, respectively, around two and three orders of magnitude lower than the levels claimed to be present by Grases et al. [3] in the fluids of experimentally phytate-deprived human subjects. These numbers make the argument that we could not detect any InsP₆ simply because we chose donors on the ‘wrong’ diet untenable.

In contrast to these claims we have, using two entirely independent specific and sensitive assays with quantified spiking recovery, unambiguously shown that InsP₆ is not present in plasma or urine. This is crucial and central to the whole debate about the actions of dietary InsP₆, because it means that InsP₆ never enters the blood. It is only absorbed after being dephosphorylated,
principally to inositol (see [1,2] for further discussion). Ironically, the most direct evidence for this lies in Dr Vucenik’s own data in experiments examining the fate of radioactive InsP₆, fed to animals, in which only inositol was detected in the blood [13]. This particular study was, as Dr Vucenik points out in her letter, conducted on mice. However, exactly the same conclusion (i.e. InsP₆ does not enter the circulation from the gut) is equally clear in her earlier study [14], which she did not cite and which was indeed on rats; does this omission ‘reflect poorly’ on Dr Vucenik’s own ‘report and the author’s credibility in culling scientific data?’

In short, dietary InsP₆ can have only two fates: it can stay in the gut, ultimately to be defecated [15], and while it is there it can chelate metal ions to alter their uptake from the gut into the body. This is no ‘straw-man’ and is certainly the most likely explanation for all of the effects of InsP₆ on cultured cells, which comprise the majority of the reports cited by Dr Vucenik. Alternatively, InsP₆ can be converted to inositol (principally by the gut microflora [15]) and be taken up as such into the circulation; were any InsP₆ to get into the blood it would in any case be rapidly dephosphorylated by the phosphatase activity we have shown to be present in human plasma [1].

For animal studies, we have raised the possibility [1,2] that it is the inositol so generated (Vitamin Bh, harmless as far as we know) that is the active mediator of any reported beneficial effects of dietary InsP₆. We note that most of the websites touting InsP₆ as a dietary supplement advocate inositol as an important (essential?) co-supplement; that the human cancer study highlighted as important by Dr Vucenik that we could examine [16] did not administer InsP₆ alone, but only in conjunction with inositol; and that in the few studies where the separate contributions of inositol and InsP₆ have been considered, there are data suggesting that it may be the inositol that matters (e.g. fig. 1 of [17]). Moreover, we are not the only ones to suggest this idea. In the Discussion of their paper (on mice) in which InsP₆ was shown not to enter the blood from the gut [13], Dr Vucenik and her colleagues state: ‘Inositol may be responsible for the antitumor actions observed in both chemopreventive and efficacy studies of IP₆… A question remains as to whether the activity of IP₆ in animal models can be replicated by administration of inositol alone because only inositol was detected in plasma and tumor after oral gavage’. Precisely.

Finally, returning to InsP₆ itself, which, incidentally, is officially classified by the FDA as a ‘fake’ cancer cure (http://www.fda.gov/drugs/guidancecomplianceregulator-yinformation/enforcementactivitiesbyfda/ucm171057.htm), our data lead inevitably to the conclusion that while InsP₆ might impact on the gut environment and thus indirectly on its microflora [2,12], its only plausible direct action on the body will be to inhibit cation uptake from the diet. Although InsP₆ binds trivalent cations with a higher affinity than divalent ions [18], it is nevertheless comparatively non-specific in this action. Administering chemicals to the diet to manipulate ion uptake is not unknown in modern medicine; for treatment of iron disorders such as haemochromatosis, as an alternative to injection of Desferal, oral administration of the closely related chelator Deferasirox is now sometimes recommended [19]. But Deferasirox is a highly iron-specific chelator, administered under close medical supervision for a directly iron-related pathology. Recommending unmonitored, widespread administration of InsP₆ to address a veritable multitude of different pathologies [20] seems to us to be an entirely different matter.

In a well-fed human, where the cation to InsP₆ ratio in the diet is high, InsP₆ may very well do no harm (it is, after all, a natural component of our diet) and there is much evidence to support this idea, as argued by Dr Vucenik. But if InsP₆ is not impacting on cation uptake from the diet to do any harm it is difficult to understand how at exactly the same time it can impact on the same uptake to do good. (See reference [21] for the studies Dr Vucenik requested ‘unequivocally demonstrating the toxicity of pure Ca-Mg-Insp₆, as it occurs naturally’ in humans with low dietary cation uptake.) In the light of the above discussion and our rigorous data, we stand unreservedly by our original closing statement [1]: ‘…that chronically altering cation absorption from the gut by artificially loading the diet with a non-specific chelator... in the hope that it might impact indirectly on cancer or other pathologies seems highly inadvisable’.

References

1. Wilson MSC, Bulley SJ, Pisani F, Irvine RF, Saiardi A. 2015 A novel method for the purification of inositol phosphates from biological samples reveals that no phytate is present in human plasma or urine. Open Biol. 5, 150014. (doi:10.1098/rsob.150014)

2. Letcher AJ, Schell MJ, Irvine RF. 2008 Do mammals make all their own inositol hexakisphosphate? Biochem. J. 416, 263–270. (doi:10.1042/BJ20081417)

3. Gases F, Simonet BM, Vucenik I, Prieto RM, Costabauza A, March JG, Shamsuddin AM. 2001 Absorption and excretion of orally administered inositol hexaphosphate (IP₆) or phytate in humans. Biofactors 15, 53–61. (doi:10.1002/biof.5520150105)

4. Munoz JA, Valiente M. 2003 Determination of phytic acid in urine by inductively coupled plasma mass spectrometry. Anal. Chem. 75, 6374–6378. (doi:10.1021/ac0345805)

5. Munoz JA, Lopez-Mesas M, Valiente M. 2010 Minimum handling method for the analysis of phosphorous inhibitors of urilithiass (pyrophosphate and phytic acid) in urine by SPE-ICP techniques. Anal. Chim. Acta 658, 204–208. (doi:10.1016/j.aca.2009.11.003)

6. Shen Y, Chen J, Ma K, Cao S, Chen X. 2007 Fluorimetric determination of phytic acid in urine based on replacement reaction. Anal. Chim. Acta 605, 185–191. (doi:10.1016/j.aca.2007.10.041)

7. Cao S, Dong N, Chen J. 2011 Synchronous fluorescence determination of phytic acid in foods stuffs and urine based on replacement reaction. Phytochem. Anal. 22, 119–123. (doi:10.1002/pca.1254)

8. March JG, Simonet BM, Gases F, Salvador A. 1998 Indirect determination of phytic acid in urine. Anal. Chim. Acta 367, 63–68. (doi:10.1016/S0003-2670(98)00164-0)

9. March JG, Simonet BM, Gases F. 2001 Determination of phytic acid by gas chromatography-mass spectroscopy: application to biological samples. J. Chromatogr. B Biomed. Sci. Appl. 757, 247–255. (doi:10.1016/S0168-0064(98)00055-4)

10. Tur F, Tur E, Lenthalic I, Mendoza P, Encabo M, Isem B, Grases F, Maraschiello C, Perello J. 2013 Validation of an LC-MS bioanalytical method for quantification of phytate levels in rat, dog, and human plasma. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 928, 146–154. (doi:10.1016/j.chromb.2013.03.023)

11. Perello J, Gases F. 2014 Phytate levels in biological fluids of mammals. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 960, 255–257. (doi:10.1016/j.chromb.2013.12.016)
12. Irvine RF. 2014 Absence of detectable inositol hexakisphosphate (phytate) in plasma. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 960, 253–254. (doi:10.1016/j.jchromb.2013.12.015)

13. Eiseman J, Lan J, Guo J, Joseph E, Vucenik I. 2011 Pharmacokinetics and tissue distribution of inositol hexaphosphate in C.B17 SCID mice bearing human breast cancer xenografts. Metab. Clin. Exp. 60, 1465–1474. (doi:10.1016/j.metabol.2011.02.015)

14. Sakamoto K, Vucenik I, Shamsuddin AM. 1993 [3H]phytic acid (inositol hexaphosphate) is absorbed and distributed to various tissues in rats. J. Nutr. 123, 713–720.

15. Wise A, Gilburt DJ. 1982 Phytate hydrolysis by germfree and conventional rats. Appl. Environ. Microbiol. 43, 753–756.

16. Basic I, Druzijanic N, Karlo R, Sklfc I, Jagic S. 2010 Efficacy of IP6 + inositol in the treatment of breast cancer patients receiving chemotherapy: prospective, randomized, pilot clinical study. J. Exp. Clin. Cancer Res. 29, 12. (doi:10.1186/1756-9966-29-12)

17. Vucenik I, Yang GY, Shamsuddin AM. 1995 Inositol hexaphosphate and inositol inhibit DMBA-induced rat mammary cancer. Carcinogenesis 16, 1055–1058. (doi:10.1093/carcin/16.5.1055)

18. Torres J, Dominguez S, Cerda MF, Obal G, Medeers A, Irvine RF, Diaz A, Kremer C. 2005 Solution behaviour of myo-inositol hexakisphosphate in the presence of multivalent cations. Prediction of a neutral pentamagnesium species under cytosolic/nuclear conditions. J. Inorg. Biochem. 99, 828–840. (doi:10.1016/j.jinorgbio.2004.12.011)

19. Yang LP, Keam S, Keating GM. 2007 Deferasirox: a review of its use in the management of transfusional chronic iron overload. Drugs 67, 2211–2230. (doi:10.2165/00003495-200767150-00007)

20. Shamsuddin AKM, Yang G-Y. 2015 Inositol and its phosphates: basic science to practical application. Bentham e-Books. Bentham Science Publishers, Sharjah, UAE. (doi:10.2174/97816810800791501001)

21. Raboy V. 2006 Seed phosphorus and low-phytate crops. In Linking agriculture and environment (eds BL Turner, AE Richardson, EJ Mullaney), pp. 111–132. Oxfordshire, UK: CAB International.